RxDoctor Payments Data

Candace Counts

Family · Ballwin, MONPI 1881044402

Payments from drug & device makers

$2,338in general payments, 2019–2025

Across 68 payments — averaging $34.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$775
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$281
  • AstraZeneca$215
  • AbbVie$205
  • Lilly USA, LLC$145
  • Edwards Lifesciences$125
  • plus $592 from 13 others

What the payments were for

  • Travel & lodging$38316%
  • Food & beverage$1,95584%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,338 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$35,504
Medicare patients
313
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban251$236,268
EntrestoSacubitril/Valsartan111$118,922
FarxigaDapagliflozin Propanediol106$97,842
JardianceEmpagliflozin53$62,942
BrilintaTicagrelor42$39,218
XareltoRivaroxaban24$32,068
OzempicSemaglutide15$22,314
Midodrine Hcl52$4,963
Metoprolol Succinate208$1,850
Rosuvastatin Calcium58$1,072
ClopidogrelClopidogrel Bisulfate87$960
Atorvastatin Calcium135$930
Losartan Potassium147$862
Amiodarone Hcl77$832
Spironolactone207$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$74$236,268251 claims
AstraZenecaFarxiga, Brilinta$215$137,060148 claims
Johnson & JohnsonXarelto$28$32,06824 claims
Novo NordiskOzempic$58$22,31415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,812 family providers in Missouri.

Other family in Ballwin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →